MX2015018032A - Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa. - Google Patents

Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.

Info

Publication number
MX2015018032A
MX2015018032A MX2015018032A MX2015018032A MX2015018032A MX 2015018032 A MX2015018032 A MX 2015018032A MX 2015018032 A MX2015018032 A MX 2015018032A MX 2015018032 A MX2015018032 A MX 2015018032A MX 2015018032 A MX2015018032 A MX 2015018032A
Authority
MX
Mexico
Prior art keywords
histone demethylase
compounds
agent known
phenylethylidene
substituted
Prior art date
Application number
MX2015018032A
Other languages
English (en)
Other versions
MX366949B (es
Inventor
David J Bearss
Steve L Warner
Sunil Sharma
Bret Stephens
SORNA Venkataswamy
Vankayalapati Hariprasad
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/921,895 external-priority patent/US9266838B2/en
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of MX2015018032A publication Critical patent/MX2015018032A/es
Publication of MX366949B publication Critical patent/MX366949B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En un aspecto, la invención se refiere a análogos sustituidos de (E)-N´-(1-feniletiliden)benzohidrazida, derivados de los mismos, y compuestos relacionados, que son útiles como inhibidores de histona desmetilasa especifica de lisina, incluyendo LSD1; métodos de síntesis para fabricar los compuestos; composiciones farmacéuticas que comprenden los compuestos; y métodos de uso de los compuestos y composiciones para tratar trastornos asociados con la disfunción de la LSD1; este resumen es ideado como una herramienta de exploración para propósitos de búsqueda en la técnica particular no pretende ser limitativo de la presente invención.
MX2015018032A 2013-06-19 2014-06-19 Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa. MX366949B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/921,895 US9266838B2 (en) 2011-08-15 2013-06-19 Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors
PCT/US2014/043179 WO2014205213A1 (en) 2013-06-19 2014-06-19 Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors

Publications (2)

Publication Number Publication Date
MX2015018032A true MX2015018032A (es) 2016-10-03
MX366949B MX366949B (es) 2019-07-30

Family

ID=52105283

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015018032A MX366949B (es) 2013-06-19 2014-06-19 Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.

Country Status (13)

Country Link
EP (1) EP3010915B1 (es)
JP (1) JP6525162B2 (es)
KR (1) KR102288648B1 (es)
CN (2) CN110015984A (es)
AU (1) AU2014281398B2 (es)
BR (1) BR112015032113B1 (es)
CA (1) CA2915817C (es)
ES (1) ES2739814T3 (es)
IL (1) IL243200B (es)
MX (1) MX366949B (es)
NZ (1) NZ715331A (es)
SG (2) SG10201710543PA (es)
WO (1) WO2014205213A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201710543PA (en) * 2013-06-19 2018-02-27 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
ES2901711T3 (es) 2014-02-13 2022-03-23 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
ME03580B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016119031A1 (pt) * 2015-01-29 2016-08-04 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composto, processo de síntese do composto, uso, composição farmacêutica, método de tratamento de inflamações ou de doença neurodegenerativa, forma de dosagem oral e método de inibição de enzima acetilcolinesterase
SG11201708047UA (en) 2015-04-03 2017-10-30 Incyte Corp Heterocyclic compounds as lsd1 inhibitors
AU2016275702A1 (en) 2015-06-12 2017-12-21 Oryzon Genomics, S.A. Biomarkers associated with LSD1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
ES2944597T3 (es) 2015-12-30 2023-06-22 Novartis Ag Terapias con células efectoras inmunitarias de eficacia mejorada
CN109195593A (zh) 2016-03-15 2019-01-11 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
AR109452A1 (es) 2016-04-22 2018-12-12 Incyte Corp Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
CN108727377A (zh) * 2017-04-14 2018-11-02 四川大学 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
SG11202000077RA (en) 2017-08-03 2020-02-27 Oryzon Genomics Sa Methods of treating behavior alterations
WO2019068326A1 (en) 2017-10-05 2019-04-11 Université D'aix-Marseille INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES
CN108689960B (zh) * 2018-06-07 2022-03-04 济南大学 5-苯亚甲基-2-苯基噻唑酮类化合物及其制备和应用
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2020188089A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
AU2020242302A1 (en) 2019-03-20 2021-09-16 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
EP3994280A1 (en) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
CN111471095B (zh) * 2020-01-15 2021-12-21 上海众启生物科技有限公司 用于阿尔茨海默症自身抗体检测的含jmjd2d蛋白片段的组合物
EP3964204A1 (en) 2020-09-08 2022-03-09 Université d'Aix-Marseille Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues
MX2023011779A (es) 2021-04-08 2023-11-22 Oryzon Genomics Sa Combinaciones de inhibidores de lsd1 para el tratamiento de canceres mieloides.
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN116813569B (zh) * 2023-07-10 2024-07-02 衡阳市中心医院 一种抗癌药中间体的制备方法和抗癌药的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0519794A2 (pt) * 2005-01-07 2009-03-17 Hoffmann La Roche derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos
WO2006136008A1 (en) * 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US20080214495A1 (en) * 2005-07-08 2008-09-04 Astrazeneca Ab Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa
EP2376440A2 (en) * 2009-01-14 2011-10-19 Dow AgroSciences LLC Fungicidal compositions including hydrazone derivatives and copper
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
CA2727890A1 (en) * 2010-01-13 2011-07-13 Norbert Kartner Compounds, compositions and treatments for v-atpase related diseases
JP2014500254A (ja) * 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
WO2013025805A1 (en) * 2011-08-15 2013-02-21 University Of Utah Research Foundation Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors
SG10201710543PA (en) * 2013-06-19 2018-02-27 Univ Utah Res Found Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors

Also Published As

Publication number Publication date
SG10201710543PA (en) 2018-02-27
WO2014205213A1 (en) 2014-12-24
MX366949B (es) 2019-07-30
IL243200B (en) 2020-10-29
EP3010915B1 (en) 2019-05-08
SG11201510376QA (en) 2016-01-28
NZ715331A (en) 2019-09-27
BR112015032113A2 (pt) 2017-03-21
AU2014281398A1 (en) 2016-01-21
ES2739814T3 (es) 2020-02-04
KR102288648B1 (ko) 2021-08-12
KR20160024929A (ko) 2016-03-07
CA2915817C (en) 2022-12-13
JP6525162B2 (ja) 2019-06-05
CN110015984A (zh) 2019-07-16
AU2014281398B2 (en) 2018-10-04
CA2915817A1 (en) 2014-12-24
EP3010915A4 (en) 2016-12-28
BR112015032113B1 (pt) 2019-01-29
IL243200A0 (en) 2016-02-29
JP2016523256A (ja) 2016-08-08
CN105555784B (zh) 2019-03-15
CN105555784A (zh) 2016-05-04
EP3010915A1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
MX366949B (es) Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA033497B1 (ru) 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
PH12017501326A1 (en) Tgf-� inhibitors
EA201691302A1 (ru) Новые гетероциклические соединения
SG10201811384TA (en) Mnk inhibitors and methods related thereto
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201991884A2 (ru) Ингибиторы g12c kras
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
MX356486B (es) Análogos sustituidos de la (e)-n' -(1-feniletiliden)benzohidrazida como inhibidores de la histona desmetilasa.
CL2015002814A1 (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
MX2016004703A (es) Forma salina de hidrocloruro para la inhibicion de ezh2.
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
HK1259405A1 (zh) N-[5-(3，5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氫吡喃-4-基氨基)-苯甲酰胺的新晶型
PH12016501462A1 (en) Neprilysin inhibitors
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
MX2015012111A (es) Moduladores de ship1 y métodos relacionados con éstos.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201692300A1 (ru) Производные карбоксамида
MX2016014946A (es) Derivados de carboxamida.
AU2013260056A8 (en) Compounds with TRPV4 activity, compositions and associated methods thereof

Legal Events

Date Code Title Description
FG Grant or registration